In brief
- The main clinical studies. Three patient-reported studies (Sewell 2006, 53 interviewed; Schindler 2015, 496 cluster headache patients surveyed; Andersson 2017, a qualitative study of forum posts), one small randomized trial in cluster headache (Schindler 2022, 14 analysed), and one small randomized trial in migraine (Schindler 2021, 10 analysed). The table below lists all eight studies.
- What the cluster headache trial found. The primary result was not statistically significant: change in attacks per week of -3.2 with psilocybin and +0.03 with placebo (p=0.251).
- What that means. The evidence is early and mostly patient-reported. Psilocybin is investigational for cluster headache, and it is not approved by the FDA for it.
- What to do with it. Read it with your neurologist. Do not start, stop or change any treatment, or add anything to your current medication, on the strength of a summary like this one.
Background: cluster headache, “the suicide headache”
Cluster headache affects roughly 0.1 percent of the population over a lifetime, with episodic and chronic patterns. Attacks are routinely rated 10/10 on pain scales, hence the colloquial name. Standard care includes oxygen therapy and triptans for acute attacks, with verapamil, CGRP-modulating monoclonals, and occipital nerve blocks for prevention. Many patients remain incompletely controlled.
The patient-led Clusterbusters community organized self-reported data on psilocybin and LSD use for cluster headaches in the early 2000s. Halpern and Sewell (2005, Life Sciences) framed that patient-led use as a research priority, a year before the first published case series (Sewell 2006, Neurology). The surveys cited below followed and, eventually, the Yale RCT program led by Schindler and colleagues.
Mechanism: hypothesized circuit involvement
Cluster headache neurobiology features trigeminovascular activation and hypothalamic involvement, demonstrated by PET imaging studies (Goadsby 2002 and successors). The serotonergic targets exploited by triptans (5-HT1B/1D agonists) have led researchers to ask whether psilocybin, through overlapping receptor pharmacology and its 5-HT2A action, could be a candidate. That is a hypothesis. The studies below do not show that it explains any effect.
The Karst et al. (2010) BOL-148 case series, using a non-hallucinogenic LSD analog, was a small open-label, non-randomized series. It is suggestive that the cluster-abortive effect may be pharmacological rather than experience-driven, but it is not proof of mechanism. Pulse protocols are studied separately from the single-session protocols used in depression and anxiety trials.

Clinical evidence: small and preliminary
The table lists all eight studies. They answer different questions, so it helps to read them in four groups.
- Patient reports (Sewell 2006; Schindler 2015; Andersson 2017). These describe what people who chose psilocybin, LSD or other psychoactive substances said afterward. The samples are self-selected and retrospective, so they cannot separate the drug from other explanations. Cluster headache has episodic patterns, so a good stretch after a dose may or may not be linked to the dose.
- Controlled trials (Schindler 2021 in migraine; Schindler 2022 in cluster headache). These used a placebo, which patient reports do not, but both are small and exploratory. The 2021 migraine trial is included as adjacent headache evidence, not as cluster headache evidence.
- Mechanism and a related compound (Goadsby 2002; Karst 2010). These explain why researchers look at serotonergic targets and report a small open-label series of a non-hallucinogenic LSD analog. Neither tests psilocybin in cluster headache.
- Background (Halpern and Sewell 2005). A review that framed the research need.
Honest caveat
Cluster-headache evidence is dominated by patient-reported survey data and one small randomized trial. The mechanism is plausible. The trial scale is small. What follows is an honest summary of the published literature; high-quality phase III data do not yet exist.
| Study | Design and sample | Primary outcome | Reported effect |
|---|---|---|---|
| Response of cluster headache to psilocybin and LSDDOI: 10.1212/01.wnl.0000219761.05466.43 | Retrospective interview-based case series | Self-reported cycle abortion, attack frequency, and remission extension | Of 53 interviewed patients, 22 of 26 psilocybin users (85%) said it aborted individual attacks, 25 of 48 (52%) reported cluster-period termination, and 18 of 19 (95%) reported remission-period extension. Retrospective, self-selected interviews; the first published case series of the patient-led use. |
| Indoleamine hallucinogens in cluster headache: results of the Clusterbusters Medication Use SurveyDOI: 10.1080/02791072.2015.1107664 | Retrospective survey (Clusterbusters cohort) | Self-reported comparative efficacy of psilocybin and LSD vs standard cluster headache abortive and preventive therapies | Survey respondents rated psilocybin and LSD as effective in cluster headache; the authors called for controlled studies. A retrospective survey of a patient-advocacy cohort. |
| Exploratory controlled study of the migraine-suppressing effects of psilocybinDOI: 10.1007/s13311-020-00962-y | Randomized, double-blind, placebo-controlled exploratory trial | Weekly migraine days post-administration | A single psychoactive dose (0.143 mg/kg, roughly 10 mg for a 70 kg adult) was followed by a reduction of 1.65 weekly migraine days (95% CI 0.77 to 2.53) after psilocybin vs 0.15 after placebo (p=0.003); crossover, n=10 analysed, exploratory (Schindler et al., 2021). |
| Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trialDOI: 10.1111/head.14420 | Randomized, double-blind, placebo-controlled (Yale) | Change in cluster attacks per week | Three doses of 0.143 mg/kg, five days apart. The primary result was not statistically significant: change in attacks per week -3.2 with psilocybin vs +0.03 with placebo (p=0.251). A 2024 blinded extension without a concurrent placebo comparator (n=10) reported attacks falling from 18.4 to 9.8 per week (Schindler et al., J Neurol Sci 2024). Small N, exploratory. |
| The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headacheDOI: 10.1177/0333102410363490 | Open, non-randomized case series | Cluster cycle abortion and remission | A small open-label, non-randomized case series of a non-hallucinogenic LSD analog; suggestive of a pathway independent of the psychedelic experience, but not proof of mechanism. |
| Pathophysiology of cluster headache: a trigeminal autonomic cephalgiaDOI: 10.1016/S1474-4422(02)00104-7 | Mechanism review | Trigeminovascular activation and hypothalamic involvement in cluster headache | Established the trigeminal-autonomic cephalgia framework and hypothalamic involvement (PET imaging), the framework researchers cite when discussing serotonergic targets. |
| Hallucinogenic botanicals of America: a growing need for focused drug education and researchDOI: 10.1016/j.lfs.2005.04.012 | Review | Public-health framing of hallucinogen pharmacology and clinical research need | Framed the patient-led use of hallucinogens for cluster headache as a research priority, preceded the 2006 Sewell case series. |
| Psychoactive substances as a last resort: a qualitative study of self-treatment of migraine and cluster headachesDOI: 10.1186/s12954-017-0186-6 | Qualitative analysis of online forum posts | Perceived effectiveness of self-treatment with psychoactive substances | Reports perceived effectiveness among self-selected forum users; not a replicated efficacy signal. |
What an exploratory headache study can answer
An exploratory randomized, placebo-controlled study investigated a low-dose psilocybin pulse regimen for cluster headache. Its purpose was to examine an early research question in a small group, not to establish a standard treatment. Headache patterns can vary between people and over time, which makes comparison and follow-up particularly important.
A person with cluster headache needs an individualized plan with a qualified clinician, including what to do during attacks and how to use established treatments. A study regimen is not a dosing guide for home use. Read the paper alongside its limitations and bring questions about ongoing symptoms or medications to your care team.
Safety profile specific to cluster headaches
Your prescriber leads any change to your headache regimen. Never stop or change a medication on your own.
- Triptans: risk of serotonin syndrome if combined acutely with psilocybin; wash-out is required and must be supervised. See Medications.
- Verapamil: talk to your prescriber before anything changes. Cardiovascular monitoring during a session is appropriate.
- Lithium and valproate (sometimes used in chronic cluster headache): lithium does not mix with this work, as the Medications guide explains. With valproate, caution; your prescriber leads any change.
- Cardiovascular pre-existing conditions: psilocybin produces transient blood pressure and heart rate elevation, relative contraindication in unstable cardiac disease. See Screening.
- Chronic vs. episodic cluster headache: the published trials and surveys distinguish these phenotypes; chronic cluster headache is a higher-bar use case for any investigational care.
Tracking and follow-up for cluster headaches
Cluster headache is primarily a neurological condition. After any treatment, the useful work looks less like psycho-spiritual reflection and more like pattern tracking: a daily headache diary, an attack frequency log, careful notes on triggers and remissions. The useful end-state is data the patient can bring back to a neurologist.
Low mood and anxiety can accompany chronic severe pain, and the framings used in the depression and anxietyresearch summaries may overlap. The Clusterbusters community uses the term “busting protocol”, a pharmacological framing, not a psychedelic-experience framing.
Questions to bring to your neurologist
If this summary raised questions, these are the ones the studies and safety notes above point to.
- Is my cluster headache episodic or chronic? The studies and surveys distinguish the two.
- Which of my current acute and preventive medications matter here, including any triptan, verapamil, lithium or valproate? Who leads any change?
- How are my heart and blood pressure? Psilocybin produces transient blood pressure and heart rate elevation.
- Are there active trials I could ask about? ClinicalTrials.gov is the primary registry; search for psilocybin or LSD studies in headache or cluster headache.
- What should I be tracking, and what would you want to see? A diary of attacks, triggers and remissions is a start.
Practitioner perspective
“Cluster headache work is a different conversation. It is primarily a neurological condition. Our job at intake is to ask whether a Ceremonia program is the right pathway at all, or whether a referral into the Yale-led trial network or a cluster-headache-specialist neurologist is the better next step.”
Thinking about your own situation?
- Read our safety overview and medication guidance. Many cluster headache medications require tapering or are absolute exclusions.
- If you are medically cleared, start with our intake conversation (free, about 30 minutes, with someone on our team). We will tell you honestly if Ceremonia is the right fit, or refer you elsewhere.
Note on scope: Cluster headache care often falls outside our typical 1:1 retreat scope. We may refer you to a neurology-led clinical trial (for example, the Yale-led psilocybin pulse research described above) or to a headache-specialist neurologist familiar with the published evidence. The intake conversation for the Heal journey is where that is decided.
We do not accept self-bookings for clinical conditions.
